H. Sano

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

K. Kaku, M. Katou, M. Igeta, 2015, Diabetes, obesity & metabolism.

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study

N. Inagaki, K. Kaku, Yoshifumi Seki, 2017, Journal of diabetes investigation.

Predictive values of serum insulin kinetics for reversion of impaired glucose tolerance to normal glucose tolerance and the effects of voglibose treatment: a retrospective post hoc analysis of a Japanese phase III study

K. Shimamoto, N. Tajima, Y. Iwamoto, 2012, Diabetology International.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

H. Ueno, K. Takeuchi, Lihong Shi, 2016, PloS one.

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

N. Inagaki, K. Kaku, H. Sano, 2014, The lancet. Diabetes & endocrinology.

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study

N. Inagaki, K. Kaku, Yoshifumi Seki, 2016, Journal of diabetes investigation.

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

K. Kaku, M. Katou, M. Igeta, 2015, Diabetes, obesity & metabolism.